Traditionally utilized for influenza treatment, OP's ability to target the CD24‐Siglec‐G/10 axis offers a strategic avenue to mitigate secondary brain injury after CA, bridging the gap between virology and neurocritical care. The gene discussed is CD24; the disease is influenza.